Cargando…
Drug-Associated Gastropathy: Diagnostic Criteria
Drugs are widely used to treat different diseases in modern medicine, but they are often associated with adverse events. Those located in the gastrointestinal tract are common and often mild, but they can be serious or life-threatening and determine the continuation of treatment. The stomach is ofte...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341309/ https://www.ncbi.nlm.nih.gov/pubmed/37443618 http://dx.doi.org/10.3390/diagnostics13132220 |
_version_ | 1785072231778353152 |
---|---|
author | Bordin, Dmitry S. Livzan, Maria A. Gaus, Olga V. Mozgovoi, Sergei I. Lanas, Angel |
author_facet | Bordin, Dmitry S. Livzan, Maria A. Gaus, Olga V. Mozgovoi, Sergei I. Lanas, Angel |
author_sort | Bordin, Dmitry S. |
collection | PubMed |
description | Drugs are widely used to treat different diseases in modern medicine, but they are often associated with adverse events. Those located in the gastrointestinal tract are common and often mild, but they can be serious or life-threatening and determine the continuation of treatment. The stomach is often affected not only by drugs taken orally but also by those administered parenterally. Here, we review the mechanisms of damage, risk factors and specific endoscopic, histopathological and clinical features of those drugs more often involved in gastric damage, namely NSAIDs, aspirin, anticoagulants, glucocorticosteroids, anticancer drugs, oral iron preparations and proton pump inhibitors. NSAID- and aspirin-associated forms of gastric damage are widely studied and have specific features, although they are often hidden by the coexistence of Helicobacter pylori infection. However, the damaging effect of anticoagulants and corticosteroids or oral iron therapy on the gastric mucosa is controversial. At the same time, the increased use of new antineoplastic drugs, such as checkpoint inhibitors, has opened up a new area of gastrointestinal damage that will be seen more frequently in the near future. We conclude that there is a need to expand and understand drug-induced gastrointestinal damage to prevent and recognize drug-associated gastropathy in a timely manner. |
format | Online Article Text |
id | pubmed-10341309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103413092023-07-14 Drug-Associated Gastropathy: Diagnostic Criteria Bordin, Dmitry S. Livzan, Maria A. Gaus, Olga V. Mozgovoi, Sergei I. Lanas, Angel Diagnostics (Basel) Review Drugs are widely used to treat different diseases in modern medicine, but they are often associated with adverse events. Those located in the gastrointestinal tract are common and often mild, but they can be serious or life-threatening and determine the continuation of treatment. The stomach is often affected not only by drugs taken orally but also by those administered parenterally. Here, we review the mechanisms of damage, risk factors and specific endoscopic, histopathological and clinical features of those drugs more often involved in gastric damage, namely NSAIDs, aspirin, anticoagulants, glucocorticosteroids, anticancer drugs, oral iron preparations and proton pump inhibitors. NSAID- and aspirin-associated forms of gastric damage are widely studied and have specific features, although they are often hidden by the coexistence of Helicobacter pylori infection. However, the damaging effect of anticoagulants and corticosteroids or oral iron therapy on the gastric mucosa is controversial. At the same time, the increased use of new antineoplastic drugs, such as checkpoint inhibitors, has opened up a new area of gastrointestinal damage that will be seen more frequently in the near future. We conclude that there is a need to expand and understand drug-induced gastrointestinal damage to prevent and recognize drug-associated gastropathy in a timely manner. MDPI 2023-06-29 /pmc/articles/PMC10341309/ /pubmed/37443618 http://dx.doi.org/10.3390/diagnostics13132220 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bordin, Dmitry S. Livzan, Maria A. Gaus, Olga V. Mozgovoi, Sergei I. Lanas, Angel Drug-Associated Gastropathy: Diagnostic Criteria |
title | Drug-Associated Gastropathy: Diagnostic Criteria |
title_full | Drug-Associated Gastropathy: Diagnostic Criteria |
title_fullStr | Drug-Associated Gastropathy: Diagnostic Criteria |
title_full_unstemmed | Drug-Associated Gastropathy: Diagnostic Criteria |
title_short | Drug-Associated Gastropathy: Diagnostic Criteria |
title_sort | drug-associated gastropathy: diagnostic criteria |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341309/ https://www.ncbi.nlm.nih.gov/pubmed/37443618 http://dx.doi.org/10.3390/diagnostics13132220 |
work_keys_str_mv | AT bordindmitrys drugassociatedgastropathydiagnosticcriteria AT livzanmariaa drugassociatedgastropathydiagnosticcriteria AT gausolgav drugassociatedgastropathydiagnosticcriteria AT mozgovoisergeii drugassociatedgastropathydiagnosticcriteria AT lanasangel drugassociatedgastropathydiagnosticcriteria |